Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase-I/II Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)

NCT04330820 is registered in ClinicalTrials.gov with Technische Universität Dresden as lead sponsor.

NCT NCT04330820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04330820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase-I/II Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)
Lead sponsor
Technische Universität Dresden
Phase
Phase 1/2
Overall status
Completed
Start date
April 6, 2020
Completion date
September 24, 2025
Enrollment
55 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

refractory aml, relapsed adult aml